Chargement en cours...
Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials
BACKGROUND: Exenatide twice daily is a first-in-class glucagon-like peptide receptor agonist approved for the treatment of type 2 diabetes. The objective of this analysis was to evaluate the safety profile of exenatide twice daily and to compare its profile with that of a pooled comparator (placebo...
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove Medical Press
2012
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3287409/ https://ncbi.nlm.nih.gov/pubmed/22375098 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S28387 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|